RxDoctor Payments Data

Boris Dilman, MD

Ophthalmology · Barrington, ILNPI 1679729628

Payments from drug & device makers

$2,029in general payments, 2019–2025

Across 65 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$426
  • Alcon$327
  • Harrow Eye, LLC$285
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$266
  • Novartis$232
  • Sun Pharmaceutical Industries Inc.$208
  • plus $285 from 8 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,029 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$722,034
Medicare patients
1,661
Services billed
8,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$76,058
LumiganBimatoprost93$63,683
Lotemax SmLoteprednol Etabonate179$46,713
ProlensaBromfenac Sodium88$30,499
SimbrinzaBrinzolamide/Brimonidine Tart53$24,391
CombiganBrimonidine Tartrate/Timolol28$17,542
Tobramycin-DexamethasoneTobramycin/Dexamethasone360$16,358
RhopressaNetarsudil Mesylate18$10,965
Travoprost37$8,640
Latanoprost611$8,579
VyzultaLatanoprostene Bunod22$6,877
Brimonidine Tartrate203$5,637
RocklatanNetarsudil Mesylat/Latanoprost14$5,607
Cyclosporine13$5,510
Brinzolamide28$4,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$29$157,283190 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$266$77,212267 claims
AlconSimbrinza$327$24,39153 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$85$16,57232 claims
Bausch & Lomb Americas Inc.Vyzulta$35$6,87722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →